| 1. |
- Clark, Andrew G., et al.
(författare)
-
Evolution of genes and genomes on the Drosophila phylogeny
- 2007
-
Ingår i: Nature. - : Springer Science and Business Media LLC. - 0028-0836 .- 1476-4687. ; 450:7167, s. 203-218
-
Tidskriftsartikel (refereegranskat)abstract
- Comparative analysis of multiple genomes in a phylogenetic framework dramatically improves the precision and sensitivity of evolutionary inference, producing more robust results than single-genome analyses can provide. The genomes of 12 Drosophila species, ten of which are presented here for the first time (sechellia, simulans, yakuba, erecta, ananassae, persimilis, willistoni, mojavensis, virilis and grimshawi), illustrate how rates and patterns of sequence divergence across taxa can illuminate evolutionary processes on a genomic scale. These genome sequences augment the formidable genetic tools that have made Drosophila melanogaster a pre-eminent model for animal genetics, and will further catalyse fundamental research on mechanisms of development, cell biology, genetics, disease, neurobiology, behaviour, physiology and evolution. Despite remarkable similarities among these Drosophila species, we identified many putatively non-neutral changes in protein-coding genes, non-coding RNA genes, and cis-regulatory regions. These may prove to underlie differences in the ecology and behaviour of these diverse species.
|
|
| 2. |
- Denton, Christopher P., et al.
(författare)
-
Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis - A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
- 2007
-
Ingår i: Arthritis and Rheumatism. - : Wiley. - 1529-0131 .- 0004-3591. ; 56:1, s. 323-333
-
Tidskriftsartikel (refereegranskat)abstract
- Objective. To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth factor beta 1 (TGF beta 1), in the treatment of early-stage diffuse cutaneous systemic sclerosis (dcSSc). Methods. Patients with SSc duration of < 18 months were randomly assigned to the placebo group or to 1 of 3 CAT-192 treatment groups: 10 mg/kg, 5 mglkg, 0.5 mg/kg. Infusions were given on day 0 and weeks 6, 12, and 18. The primary objective of this study was to evaluate the safety, tolerability, and pharmacokinetics of CAT-192. Secondary outcomes included the modified Rodnan skin thickness score (MRSS), the Scleroderma Health Assessment Questionnaire, assessment of organ-based disease, serum levels of soluble interleukin-2 receptor, collagen propeptides (N propeptide of type I [PINP] and type III collagen), and tissue levels of messenger RNA for procollagens I and III and for TGF beta 1 and TGF beta 2. Results. Forty-five patients were enrolled. There was significant morbidity and mortality, including I death in the group receiving 0.5 mg/kg of CAT-192 and 3 deaths in the group receiving 5 mg/kg of CAT-192. There were more adverse events and more serious adverse events in patients receiving CAT-192 than in those receiving placebo, although these events were not more frequent in the high-dose treatment group. The MRSS improved in all groups during the study, but there was no evidence of a treatment effect for CAT-192. Improvement in the MRSS correlated with the disease duration (r = -0.54, P = 0.0008). Changes in the PINP level from baseline correlated with changes in the MRSS (r = 0.37, P = 0.027). Conclusion. We report the first evaluation of a systemically administered and repeatedly dosed anti-TGF beta 1 drug. In this pilot study, CAT-192, in doses up to 10 mg/kg, showed no evidence of efficacy. The utility of clinical and biochemical outcome measures and the feasibility of multicenter trials of early dcSSc were confirmed.
|
|
| 3. |
- Druker, Brian J., et al.
(författare)
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
- 2006
-
Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 355:23, s. 2408-2417
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events. CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343 [ClinicalTrials.gov].)
|
|
| 4. |
|
|
| 5. |
- Al-Mashikhi, S.O., et al.
(författare)
-
An explanation of ‘striation free' cutting of mild steel by fibre laser
- 2009
-
Ingår i: Lasers in manufacturing 2009. - Stuttgart : AT-Fachverlag.
-
Konferensbidrag (refereegranskat)abstract
- This paper presents the results of an experimental and theoretical investigation into the phenomenon of ‘striation free cutting', which is a feature of fibre laser cutting of thin section mild steel. The paper concludes that the creation of very low roughness edges is related to an optimisation of the cut front geometry when the cut front is inclined at angles close to the Brewster angle for the laser - material combination. For purely geometric reasons this particular type of cut front optimisation is not possible for CO2 laser cutting of mild steel.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Andersson, Roger, et al.
(författare)
-
Formability behaviour of meta-stable stainless steels
- 2005
-
Ingår i: Proceedings of the 8th ESAFORM Conference on Material Forming. - Bucharest : The Romanian Academy Publishing House. - 9732711736 ; , s. 359-362
-
Konferensbidrag (refereegranskat)
|
|
| 9. |
- Bergström, David, et al.
(författare)
-
A ray-tracing analysis of the absorption of light by smooth and rough metal surfaces
- 2007
-
Ingår i: Journal of Applied Physics. - : AIP Publishing. - 0021-8979 .- 1089-7550. ; 101:11, s. 113504-1
-
Tidskriftsartikel (refereegranskat)abstract
- Ray tracing has been employed to investigate the absorption of light by smooth and random rough metal surfaces. For normally incident light the absorptance of the surface increases with surface roughness. However, for light incident at a tangent to the surface the absorptance-surface roughness relationship is more complex. For example, in certain cases the absorptance can rise, fall, and rise again as the surface roughness increases. In this paper this complex absorptance-roughness relationship is defined and explained. The wavelengths of the light chosen for this study correspond to the primary and secondary output wavelengths of Nd:YAG lasers.
|
|
| 10. |
- Bergström, David, et al.
(författare)
-
Absorptance of Non-Ferrous Alloys to Nd:YLF and Nd:YAG Laser Light at Room Temperature
- 2007
-
Ingår i: Applied Optics. - 1559-128X .- 2155-3165. ; 46:8, s. 1290-1301
-
Tidskriftsartikel (refereegranskat)abstract
- The measurement of absorptance is important for the analysis and modelling of laser-material interactions. Unfortunately, most of the absorptance data presently available considers only polished pure metals rather than the commercially available (unpolished, oxidised) alloys which are actually being processed in manufacturing. This paper presents the results of absorptance measurements carried out at room temperature on as-received engineering grade non-ferrous metals (Al, Cu and Zn alloys). The measurements were made using an integrating sphere with an Nd:YLF laser at two wavelengths (1053nm and 527nm � which means that the results are also valid for Nd:YAG radiation at 1064nm and 532nm). The absorptance results obtained differ considerably from existing data for polished, pure metals and should help improve the accuracy of laser-material interaction models. Some clear trends were identified. For all 22 cases studied the absorptance was higher than for ideal pure, polished metals. For all Al- and Cu-samples the absorptance was higher for the green than it was for the infrared wavelength, while for all Zn-coatings this trend was reversed. No clear correlation between absorptance and surface roughness was found at low roughness values (Sa 0.15 � 0.60) but one, rougher set of samples (Sa 2.34), indicated a roughness-absorptance correlation at higher roughness levels.
|
|
